Caplin Point Laboratories Ltd

Caplin Point Lab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Caplin Point Laboratories Ltd

₹ 2,024 0.06%
29 May - close price
caplinpoint.net BSE: 524742 NSE: CAPLIPOINT
About

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

Key Points

Product Portfolio
The company offers a range of pharmaceutical products, with 4,000+ registered licenses and 650 formulations across 36 therapeutic areas. Its product line includes more than 65% of the drugs on the WHO essential drug list. The portfolio features various forms like tablets, capsules, injections, eye drops, oral liquids, soft gel capsules, ointments, creams, gels, injectable powders, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. [1] [2]

Website BSE NSE
  • Market Cap ₹ 15,389 Cr.
  • Current Price ₹ 2,024
  • High / Low ₹ 2,397 / 1,500
  • Stock P/E 38.8
  • Book Value ₹ 270
  • Dividend Yield 0.30 %
  • ROCE 27.0 %
  • ROE 21.1 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 21.2% CAGR over last 5 years

Cons

  • Stock is trading at 7.50 times its book value
  • The company has delivered a poor sales growth of 8.87% over past five years.
  • Earnings include an other income of Rs.195 Cr.
  • Debtor days have increased from 97.2 to 131 days.
  • Working capital days have increased from 161 days to 309 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE 250 SmallCap Index BSE 400 MidSmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
145 174 179 133 139 186 208 185 174 183 175 189 191
80 97 90 70 82 104 110 108 99 96 99 98 108
Operating Profit 65 77 89 63 58 81 98 77 75 87 76 92 84
OPM % 45% 44% 50% 48% 41% 44% 47% 42% 43% 47% 43% 48% 44%
12 27 24 18 36 22 43 29 41 32 59 32 61
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 6 7 7 7 7 6 6 6 6 6 6 6 7
Profit before tax 71 97 107 74 87 97 135 100 110 112 129 117 138
Tax % 23% 22% 23% 26% 20% 25% 21% 25% 21% 24% 20% 25% 20%
54 76 82 55 70 73 106 75 86 86 103 87 110
EPS in Rs 7.16 10.04 10.81 7.30 9.20 9.54 13.91 9.83 11.38 11.30 13.50 11.48 14.41
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Jun 2015 Mar 2016 9m Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
240 231 342 427 537 528 483 528 529 625 752 738
183 169 248 284 348 321 269 308 308 337 417 401
Operating Profit 57 63 94 142 189 207 214 220 220 288 336 338
OPM % 24% 27% 27% 33% 35% 39% 44% 42% 42% 46% 45% 46%
3 3 13 23 35 66 19 56 99 105 131 195
Interest 1 0 0 1 0 0 0 0 0 0 0 0
Depreciation 8 7 13 19 21 20 22 26 26 27 25 25
Profit before tax 51 58 93 146 203 253 210 250 293 366 442 508
Tax % 19% 22% 24% 30% 27% 22% 26% 25% 20% 22% 23% 22%
41 45 70 102 148 198 156 188 234 284 339 397
EPS in Rs 5.42 6.00 9.30 13.53 19.59 26.13 20.65 24.79 30.86 37.36 44.66 52.17
Dividend Payout % 18% 20% 16% 15% 11% 10% 15% 16% 15% 13% 13% 8%
Compounded Sales Growth
10 Years: 12%
5 Years: 9%
3 Years: 12%
TTM: -2%
Compounded Profit Growth
10 Years: 24%
5 Years: 21%
3 Years: 19%
TTM: 17%
Stock Price CAGR
10 Years: 26%
5 Years: 28%
3 Years: 39%
1 Year: -6%
Return on Equity
10 Years: 25%
5 Years: 22%
3 Years: 22%
Last Year: 21%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 15 15 15 15 15 15 15 15 15 15 15 15
Reserves 79 113 185 280 417 585 744 915 1,125 1,375 1,686 2,035
2 2 1 1 1 2 1 1 1 1 2 2
128 132 116 115 107 89 101 123 162 131 112 159
Total Liabilities 223 263 317 411 539 691 861 1,054 1,303 1,522 1,814 2,212
111 143 152 169 138 167 183 162 157 166 205 223
CWIP 31 0 3 15 9 4 1 3 43 28 21 9
Investments 1 1 19 48 168 196 149 265 485 584 802 1,047
80 118 143 178 225 325 528 624 618 745 786 932
Total Assets 223 263 317 411 539 691 861 1,054 1,303 1,522 1,814 2,212

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
50 44 55 23 107 87 295 231 157 111 196 215
-24 -6 -37 -60 -76 -41 -4 -276 -86 -118 -139 -225
-9 -14 -7 -12 -15 -33 -3 -23 -30 -34 -38 -46
Net Cash Flow 17 24 12 -49 16 13 287 -68 41 -41 19 -56
Free Cash Flow 24 36 30 -26 47 38 252 224 98 88 139 170
CFO/OP 103% 88% 81% 40% 79% 66% 163% 133% 101% 69% 89% 96%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 0 11 3 74 85 151 74 37 61 75 85 131
Inventory Days 36 56 50 58 36 34 47 76 95 153 102 137
Days Payable 108 161 149 148 92 79 131 116 130 140 93 148
Cash Conversion Cycle -72 -94 -95 -16 30 107 -10 -2 26 89 93 120
Working Capital Days -125 -112 -44 44 62 137 60 96 23 76 97 309
ROCE % 64% 60% 56% 58% 55% 48% 30% 29% 28% 29% 29% 27%

Insights

In beta
Jun 2015 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Products Registered (Global Licenses)
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of Therapeutic Segments Covered
Number
R&D Team Strength (Total Professionals/Scientists)
Number
Market Presence (Number of Countries)
Countries
USFDA Approved ANDAs (Cumulative)
Number
Receivables Days
Days
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
70.63% 70.62% 70.62% 70.62% 70.56% 70.56% 70.56% 70.56% 70.56% 70.57% 70.57% 70.57%
2.68% 3.09% 2.84% 3.33% 3.38% 3.71% 4.86% 5.73% 6.16% 6.51% 6.58% 6.15%
0.27% 0.21% 0.43% 1.08% 1.49% 1.83% 2.11% 2.00% 2.22% 2.10% 2.05% 2.14%
26.44% 26.08% 26.11% 24.95% 24.59% 23.93% 22.48% 21.72% 21.06% 20.82% 20.81% 21.14%
No. of Shareholders 78,95678,06879,43881,40980,41196,12392,70296,38794,16993,75393,70593,896

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls